To reduce off-target hERG toxicity while maintaining the desired therapeutic effects of a T-type calcium channel blocker, medicinal chemists and drug developers focus on making structural modifications to the compound. These modifications are aimed at improving the selectivity of the compound for its intended target (T-type calcium channels) while minimizing its interaction with hERG channels. Common structural modifications include altering the chemical structure of the compound to change its binding affinity and selectivity. This can involve adding or removing functional groups, adjusting the compound's size, or modifying its charge distribution to reduce hERG channel inhibition.
If you need to purchase chemical raw materials, submit your demand information to get the latest quotations.
C26H33BrN2O4
4-Quinolinamine,7-chloro-N-[4-(4-methyl-1-piperazinyl)phenyl]-
methyl 3-{N-(1-butyl)-2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}benzamido}benzoate
ETHYL (S)-(-)-2-((METHYLSULFONYL)OXY)-PROPIONATE, TECH., 90
ETHYL MANDELATE
C26H23FO6
Benzene, 1,3,5-tris[2-(4-bromophenyl)ethynyl]-
C25H32N4O3
3-(1-Naphthyl)acrylic acid
1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-5-(4-methylphenyl)-, ethyl ester
L-TYROSINE, ACETATE (ESTER, HOMOPOLYMER)
betulafolienetriol
Benzene, 1,2,3-trimethoxy-5-[(1E)-2-(4-methoxy-3-nitrophenyl)ethenyl]-
